RenovoRx Inc (RenovoRx) is a medical device company. The company develops solutions for targeted delivery of diagnostic, therapeutic agents and chemotherapeutic drugs targeting peripheral vascular system. Its proprietary Trans-Arterial Micro-Perfusion (TAMP), technology platform provides chemotherapy for the treatment of solid tumors in the peripheral system. RenovoRx lead product RenovoCath, a medical device system with dual-balloon infusion catheter that delivers intra-arterial chemotherapy directly to the tumor. It also investigating TIGeR-PaC, a systemic chemotherapy for pancreatic cancer. RenovoRx is headquartered in Los Altos, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company RenovoRx Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- RenovoRx Inc Company Overview
- RenovoRx Inc Company Snapshot
- RenovoRx Inc Pipeline Products and Ongoing Clinical Trials Overview
- RenovoRx Inc - Pipeline Analysis Overview
- RenovoRx Inc - Key Facts
- RenovoRx Inc - Major Products and Services
- RenovoRx Inc Pipeline Products by Development Stage
- RenovoRx Inc Ongoing Clinical Trials by Trial Status
- RenovoRx Inc Pipeline Products Overview
- RenovoCath System - Bile Duct Cancer
- RenovoCath System - Bile Duct Cancer Product Overview
- RenovoCath System - Pancreatic Cancer
- RenovoCath System - Pancreatic Cancer Product Overview
- RenovoCath System - Pancreatic Cancer Clinical Trial
- Retractable Coil - Interventional Oncology
- Retractable Coil - Interventional Oncology Product Overview
- RenovoRx Inc - Key Competitors
- RenovoRx Inc - Key Employees
- RenovoRx Inc - Locations And Subsidiaries
- Head Office
- Recent Developments
- RenovoRx Inc, Recent Developments
- Apr 04, 2025: Renovorx To Present at LD Micro Invitational XV Conference in New York on April 10th
- Mar 28, 2025: RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
- Mar 26, 2025: RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
- Mar 19, 2025: Renovorx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
- Feb 13, 2025: Renovorx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential To Improve Localized and Targeted Drug Delivery
- Jan 27, 2025: Renovorx Highlights Promising Pharmacokinetic Data Abstract Presented at Asco GI 2025
- Jan 08, 2025: Renovorx Announces Acceptance of Abstract for Presentation at Asco Gastrointestinal Cancers Symposium 2025
- Dec 30, 2024: Renovorx Continues To Grow Intellectual Property Portfolio for Its Novel Drug-Delivery Therapy Platform
- Dec 11, 2024: Renovorx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III Tiger-Pac Clinical Trial in Locally Advanced Pancreatic Cancer
- Dec 06, 2024: RenovoRx begins commercialisation of RenovoCath device
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- RenovoRx Inc Pipeline Products and Ongoing Clinical Trials Overview
- RenovoRx Inc Pipeline Products by Equipment Type
- RenovoRx Inc Pipeline Products by Indication
- RenovoRx Inc Ongoing Clinical Trials by Trial Status
- RenovoRx Inc, Key Facts
- RenovoRx Inc, Major Products and Services
- RenovoRx Inc Number of Pipeline Products by Development Stage
- RenovoRx Inc Pipeline Products Summary by Development Stage
- RenovoRx Inc Ongoing Clinical Trials by Trial Status
- RenovoRx Inc Ongoing Clinical Trials Summary
- RenovoCath System - Bile Duct Cancer - Product Status
- RenovoCath System - Bile Duct Cancer - Product Description
- RenovoCath System - Pancreatic Cancer - Product Status
- RenovoCath System - Pancreatic Cancer - Product Description
- RenovoCath System - Pancreatic Cancer - Targeted Intra-arterial Gemcitabine Versus Continuation of IV Gemcitabine Plus Nab-paclitaxel Following Induction with Sequential IV Gemcitabine Plus Nab-paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer
- Retractable Coil - Interventional Oncology - Product Status
- Retractable Coil - Interventional Oncology - Product Description
- RenovoRx Inc, Key Employees
- Glossary
- RenovoRx Inc Pipeline Products by Equipment Type
- RenovoRx Inc Pipeline Products by Development Stage
- RenovoRx Inc Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biomerix Corporation
- Amgen Inc
- Johnson & Johnson
